VYEPTI (eptinezumab-jjmr)

There are 0 contraindications.

Drug contraindication overview.

*Serious hypersensitivity to eptinezumab or to any excipients in the formulation.

Adverse reaction overview.

Adverse reactions reported in >=2% of patients receiving eptinezumab-jjmr for preventive treatment of migraine in clinical studies and >=2% more frequently than with placebo include nasopharyngitis and hypersensitivity reactions.

The manufacturer states that the safety and efficacy of eptinezumab have not been established in pediatric patients. Pending further clinical experience with the use of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in pediatric patients, the Pediatric and Adolescent Headache special interest group of the American Headache Society (AHS) recommends that anti-CGRP monoclonal antibodies should be considered mainly for use in postpubertal adolescents+ with relatively frequent migraines (i.e., 8 or more headache days per month) who have moderate to severe disability associated with migraine (e.g., PedMIDAS score of 30 or more) and in whom at least 2 preventive therapies (including pharmacologic and nonpharmacologic therapies and dietary supplements) have failed. For younger pediatric patients+ with severe chronic migraine that is refractory to multiple preventive therapies, these experts recommend that anti-CGRP monoclonal antibodies be considered only in carefully selected patients with close monitoring (e.g., pubertal status, bone health, linear growth, weight, body mass index (BMI), infectious complications).

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None